This initiative identified the 10 net price increases occurring in 2023 that had the largest impact on national drug spending and determine whether new clinical evidence existed that could support those price increases.

For questions or additional information, please contact info@icer.org.

Final Documents

Unsupported Price Increase Final ReportDownload

ICER’s Vice President of Research Foluso Agboola, MBBS, MPH stated:

“We continue to see list price increases that are far above the rate of inflation for many of the costliest drugs. These price hikes resulted in over $800 million in excess costs to the US health care system in just one year alone. This impacts everyone in the country, especially patients and their families. Over the past few years, ICER has played a role in highlighting substantial price increases. Since launching this report in 2019, we have noticed a decrease in the number of drugs that have significant price hikes without any new clinical evidence. In this report, half of the drugs we assessed had price increases in the setting of new evidence of additional benefits or reduced harm, while the other half lacked such evidence to support their higher price tag.”